BIND Therapeutics falls in 1st day on Nasdaq

NEW YORK (AP) - Shares of drug developer BIND Therapeutics fell in its first day of trading on the Nasdaq.

The stock dropped 91 cents, or 6.1 percent, to close at $14.09 Friday after raising $70.5 million in an initial public offering of stock.

BIND Therapeutics Inc. priced the offering of 4.7 million shares at $15 each, in the middle of the expected range.

BIND Therapeutics has no products on the market. Its most advanced treatment candidate, BIND-014, is in mid-stage clinical development as a possible treatment for a form of lung cancer and an advanced form of prostate cancer. The company plans to use the offering's proceeds in part to fund BIND-014 development.

The Cambridge, Mass., company trades under the "BIND" ticker symbol.


(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

Top Stories

  • Quick and Profitable
    Ron and Don say it's time to cut off Seattle's presidential ATM

  • Concert Congestion
    Concertgoers are crying foul after missing the Journey-Steve Miller show for a traffic jam

  • Seeking a Sequel
    Danny O'Neil has 3 things things to watch for as the Seahawks start training camp
ATTENTION COMMENTERS: We've changed our comments, but want to keep you in the conversation.
Please login below with your Facebook, Twitter, Google+ or Disqus account. Existing MyNorthwest account holders will need to create a new Disqus account or use one of the social logins provided below. Thank you.
comments powered by Disqus
Sign up for breaking news e-mail alerts from MyNorthwest.com
In the community
Do you know an exceptional citizen who has impacted and inspired others?
KIRO Radio and WSECU would like to recognize six oustanding citizens this year. Nominate them to be recognized and to receive a $2,000 charitable grant.